그레이브스병의 내과적 치료 = Medical Treatment of Graves’ Disease

다국어 초록 (Multilingual Abstract)

Among the three treatment modalities of Graves’ disease which include antithyroid drug (ATD), radioactive iodine and surgery, the ATD is most commonly preferred in Korea due to ease of use and definite curative effects on the thyrotoxic symptoms. However, several uncertainties about ATD remain: for example, the mechanism of actions on immune modulation, differences in the effects of drugs among individuals and associated factors in the view of remission. In recent years, long-term ATD treatment has been confirmed as an effective and safe therapy modality in adults, and several treatment guidelines have been released which accept long-term ATD therapy as an acceptable alternative to ablative therapy in Graves’ patients. In this review, we summarize the recent progress in understanding the clinical role of ATD and emerging new antithyroid drugs focusing on immunomodulation.

참고문헌 (Reference)

1 김원배, "갑상선자극호르몬 결합억제 면역글로불린(TBII) 측정법의 임상적 이용" 대한내분비학회 23 (23): 174-178, 2008

2 권혜미, "Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease" 대한내분비학회 31 (31): 300-310, 2016

3 Tun NN, "Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves' disease relapse" 26 (26): 1004-1009, 2016

4 Smith BR, "The thyroid-stimulating properties of long-acting thyroid stimulator gamma G-globulin subunits" 192 (192): 277-285, 1969

5 Bandai S, "The long-term follow-up of patients with thionamide-treated Graves' hyperthyroidism" 66 (66): 535-545, 2019

6 Quadbeck B, "Sensitive thyrotropin and thyrotropinreceptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves'disease" 15 (15): 1047-1054, 2005

7 Hertz BE, "Saul Hertz, MD (1905-1950): a pioneer in the use of radioactive iodine" 16 (16): 713-715, 2010

8 Hiraiwa T, "Restriction of dietary Iodine does not ameliorate the early effect of anti-thyroid drug therapy for Graves' disease in an area of excessive iodine intake" 29 (29): 380-384, 2006

9 Solomon BL, "Remission rates with antithyroid drug therapy: continuing influence of iodine intake?" 107 (107): 510-512, 1987

10 Takasu N, "Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment" 10 (10): 891-896, 2000

11 Prakash R, "Prediction of remission in Graves' disease treated with long-term carbimazole therapy: evaluation of technetium-99m thyroid uptake and TSH concentrations as prognostic indicators" 23 (23): 118-122, 1996

12 Vos XG, "Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism" 101 (101): 1381-1389, 2016

13 Rotondi M, "Post-partum and non-post-partum relapsing Graves' hyperthyroidism display different response to anti-thyroid drugs" 178 (178): 589-594, 2018

14 Leger J, "Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study" 97 (97): 110-119, 2012

15 Mazza E, "Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study" 31 (31): 866-872, 2008

16 Azizi F, "Long-term antithyroid drug treatment:a systematic review and meta-analysis" 27 (27): 1223-1231, 2017

17 Codaccioni JL, "Lasting remissions in patients treated for Graves'hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease" 67 (67): 656-662, 1988

18 Astwood EB, "Landmark article May 8, 1943: Treatment of hyperthyroidism with thiourea and thiouracil. By E.B. Astwood" 251 (251): 1743-1746, 1984

19 Azizi F, "Increased remission rates after long-term methimazole therapy in patients with Graves' disease: results of a randomized clinical trial" 29 (29): 1192-1200, 2019

20 Furmaniak J, "In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70)" 3 (3): 19-25, 2012

21 Choo YK, "Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease" 20 (20): 949-954, 2010

22 Wood LC, "Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents" 64 (64): 1429-1436, 1979

23 Cho BY, "Hyperthyroidism: Graves’ disease. Clinical thyroidolgy" Korea Medical Book 219-284, 2014

24 Lippe BM, "Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years" 64 (64): 1241-1245, 1987

25 Astwood EB, "Further studies on the chemical nature of compounds which inhibit the function of the thyroid gland" 37 : 456-481, 1945

26 Park SM, "Excessive iodine intake does not increase the recurrence rate of graves' disease after withdrawal of the antithyroid drug in an iodine-replete area" 4 (4): 36-42, 2015

27 Kahaly GJ, "European Thyroid Association guideline for the management of Graves' hyperthyroidism" 7 (7): 167-186, 2018

28 Kim TY, "Epitope heterogeneity of thyroid-stimulating antibodies predicts long-term outcome in Graves' patients treated with antithyroid drugs" 88 (88): 117-124, 2003

29 Tatara MR, "Effects of long-term oral administration of methimazole on femur and tibia properties in male Wistar rats" 94 : 124-128, 2017

30 Rittmaster RS, "Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease" 83 (83): 814-818, 1998

31 El Fassi D, "B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study" 92 (92): 1769-1772, 2007

32 Brito JP, "Antithyroid drugs-the most common treatment for Graves' disease in the United States:a nationwide population-based study" 26 (26): 1144-1145, 2016

33 Pearce SHS, "Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism: a phase I study" 29 (29): 1003-1011, 2019

34 Adams DD, "Abnormal responses in the assay of thyrotropin" 34 : 11-12, 1956

35 Abraham P, "A systematic review of drug therapy for Graves' hyperthyroidism" 153 (153): 489-498, 2005

36 Ross DS, "2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis" 26 (26): 1343-1421, 2016